Compass Therapeutics Quarterly Income Statement
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.6882+0.0097 (+1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics revenue and earnings
Compass Therapeutics reported a net loss of $27.2 million, compared with a loss of $14.3 million a year earlier.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics income statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | — | 0 | 0 | 850.00K | — | 0 |
| Revenue growth (YoY) | — | — | — | — | — | -100.00% | — | — | — | — | — | — |
| Operating Expenses | 28.80M | 26.98M | 20.30M | 17.99M | 15.82M | 21.07M | 17.97M | 16.57M | 12.24M | 15.89M | 12.77M | 15.39M |
| Research & Development | 22.04M | 19.58M | 13.39M | 13.67M | 12.83M | 16.41M | 13.05M | 13.04M | 8.61M | 11.17M | 9.52M | 12.43M |
| Operating Income | -28.80M | -26.98M | -20.30M | -17.99M | -15.82M | -21.07M | -17.97M | -16.57M | -12.24M | -15.04M | -12.77M | -15.39M |
| Other Income (Expense) | 1.63M | 1.82M | 1.98M | 2.27M | 1.56M | 1.19M | 1.33M | 1.54M | 1.76M | 1.97M | 1.98M | 1.98M |
| Pretax Income | — | — | — | — | — | — | -16.63M | — | — | -13.08M | -10.79M | -13.41M |
| Income Tax | — | — | — | — | — | — | 0 | — | — | 0 | 0 | 0 |
| Net Income | -27.17M | -25.15M | -18.32M | -15.72M | -14.26M | -19.88M | -16.63M | -15.03M | -10.48M | -13.08M | -10.79M | -13.41M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.15 | -0.13 | -0.10 | -0.08 | -0.08 | -0.14 | -0.12 | -0.10 | -0.08 | -0.10 | -0.08 | -0.10 |
| Shares Outstanding (Basic) | 186.80M | 186.80M | 186.40M | — | 168.78M | 138.28M | 138.24M | — | 137.59M | 137.59M | 136.61M | — |
| Shares Outstanding (Diluted) | — | — | — | — | — | — | 138.20M | — | 137.60M | — | — | — |
| EBITDA | -28.77M | -26.96M | -20.28M | -17.97M | -15.80M | -20.97M | -17.83M | -16.43M | -12.10M | -14.89M | -12.62M | -15.23M |
| Operating Margin | — | — | — | — | — | — | — | — | — | -1770.00% | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | -1538.35% | — | — |
This table shows 12 quarterly periods of Compass Therapeutics's income statement, from Q3 2026 back to Q4 2023, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a income statement?